BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
112.37
+8.87 (8.57%)
Sep 5, 2025, 3:37 PM - Market open
BioNTech SE Revenue
BioNTech SE had revenue of 260.80M EUR in the quarter ending June 30, 2025, with 102.64% growth. This brings the company's revenue in the last twelve months to 2.88B, up 6.98% year-over-year. In the year 2024, BioNTech SE had annual revenue of 2.75B, down -27.96%.
Revenue (ttm)
2.88B EUR
Revenue Growth
+6.98%
P/S Ratio
7.37
Revenue / Employee
425,044 EUR
Employees
6,772
Market Cap
27.01B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.75B | -1.07B | -27.96% |
| Dec 31, 2023 | 3.82B | -13.49B | -77.94% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BNTX News
- 10 hours ago - BioNTech, Duality score initial trial win with breast cancer precision drug - Reuters
- 8 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 9 days ago - Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 - Business Wire
- 4 weeks ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 4 weeks ago - These Analysts Revise Their Forecasts On BioNTech After Q2 Results - Benzinga
- 4 weeks ago - BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
- 4 weeks ago - BioNTech Stock Rises as Drug Maker Beats Earnings Expectations. - Barrons